Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act.
作者信息
Chambers James D, Clifford Katherine A, Enright Daniel E, Neumann Peter J
机构信息
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts.
出版信息
JAMA Netw Open. 2023 Aug 1;6(8):e2329006. doi: 10.1001/jamanetworkopen.2023.29006.
Abstract
摘要
相似文献
1
Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act.与《降低通胀法案》相关的孤儿药后续适应症
JAMA Netw Open. 2023 Aug 1;6(8):e2329006. doi: 10.1001/jamanetworkopen.2023.29006.
2
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.2005 - 2014年美国支持处方药补充适应症获批的疗效证据特征：系统评价
BMJ. 2015 Sep 23;351:h4679. doi: 10.1136/bmj.h4679.
3
Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.1999 年至 2018 年美国食品和药物管理局数据库的上市后孤儿药安全性：纵向分析。
Orphanet J Rare Dis. 2022 Jan 4;17(1):3. doi: 10.1186/s13023-021-02166-9.
4
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.支持孤儿药和非孤儿药获批用于癌症的临床试验特征。
JAMA. 2011 Jun 8;305(22):2320-6. doi: 10.1001/jama.2011.769.
5
Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years.美国孤儿药的出现：对前 25 年的定量评估。
Nat Rev Drug Discov. 2010 Jul;9(7):519-22. doi: 10.1038/nrd3160. Epub 2010 Jun 7.
6
Pediatric Orphan Drug Indications: 2010-2018.儿科罕用药适应证：2010-2018 年。
Pediatrics. 2020 Apr;145(4). doi: 10.1542/peds.2019-3128. Epub 2020 Mar 3.
7
Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases.用于治疗常见疾病的畅销孤儿药的孤儿适应症支出。
Health Aff (Millwood). 2021 Mar;40(3):453-460. doi: 10.1377/hlthaff.2020.01442.
8
Investigating the landscape of US orphan product approvals.调查美国孤儿药批准的全景。
Orphanet J Rare Dis. 2018 Oct 22;13(1):183. doi: 10.1186/s13023-018-0930-3.
9
Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18.美国孤儿药支出：2007 - 2018年的历史与前瞻性分析
Health Aff (Millwood). 2016 Sep 1;35(9):1588-94. doi: 10.1377/hlthaff.2016.0030.
10
The prevalence and cost of unapproved uses of top-selling orphan drugs.畅销孤儿药的未批准用途的流行率和成本。
PLoS One. 2012;7(2):e31894. doi: 10.1371/journal.pone.0031894. Epub 2012 Feb 21.
引用本文的文献
1
The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials.《降低通胀法案》与药物研发：对批准后临床试验影响的潜在早期信号
Ther Innov Regul Sci. 2025 Apr 22. doi: 10.1007/s43441-025-00774-2.
2
Evidence available and used by the Food and Drug Administration for the approval of orphan and nonorphan drugs.美国食品药品监督管理局用于批准孤儿药和非孤儿药的现有证据及所使用的证据。
Health Aff Sch. 2025 Mar 18;3(4):qxaf057. doi: 10.1093/haschl/qxaf057. eCollection 2025 Apr.
3
Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act.肿瘤药物的后续适应症：途径、时间表与《降低通胀法案》
Ther Innov Regul Sci. 2025 Jan;59(1):102-111. doi: 10.1007/s43441-024-00706-6. Epub 2024 Oct 6.
Zotero 插件